TP53 and neuroblastoma: A novel CRISPR-barcoding tool utilizing HDR enables identification of mutation such as p53 mutation in breast cancer cells (MCF7) and even correcting a mutation, for example, ALK-F1174L in Kelly neuroblastoma cells [344].